[CPRX] Catalyst Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 1.09 Change: 0 (0%)
Ext. hours: Change: 0 (0%)

chart CPRX

Refresh chart

Strongest Trends Summary For CPRX

CPRX is in the long-term up 355% in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Catalyst Pharmaceutical Partners, Inc. operates as development-stage specialty pharmaceutical company. The company focuses on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases and disorders. Its principal product candidate is Firdapse, a proprietary form of amifampridine phosphate, which is in Phase III clinical trial for the treatment of Lambert-Eaton Myasthenic Syndrome. The company also develops CPP-115, a vigabatrin analog to treat infantile spasms and epilepsy, as well as other neurological conditions associated with reduced GABAergic signaling, such as post-traumatic stress disorder and Tourette syndrome. Catalyst Pharmaceutical Partners, Inc. has strategic collaboration agreement with BioMarin. The company was founded in 2002 and is based in Coral Gables, Florida.

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-22.5% ROE-25.68% ROI
Current Ratio12.99 Quick Ratio Long Term Debt/Equity Debt Ratio0.09
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities36.06 M Cash From Investing Activities-40 K Cash From Operating Activities-3.79 M Gross Profit
Net Profit-5.41 M Operating Profit-4.29 M Total Assets76.05 M Total Current Assets75.97 M
Total Current Liabilities5.85 M Total Debt Total Liabilities9.43 M Total Revenue
Technical Data
High 52 week3.84 Low 52 week1.92 Last close2.88 Last change-1.03%
RSI77.42 Average true range0.13 Beta0.6 Volume310.27 K
Simple moving average 20 days11.78% Simple moving average 50 days18.31% Simple moving average 200 days-3.21%
Performance Data
Performance Week3.97% Performance Month16.13% Performance Quart3.23% Performance Half-3.03%
Performance Year-8.57% Performance Year-to-date50% Volatility daily3.02% Volatility weekly6.74%
Volatility monthly13.82% Volatility yearly47.87% Relative Volume298.06% Average Volume1.79 M
New High New Low

News

2019-06-12 09:46:42 | UPDATE 2-Catalyst Pharma sues FDA over approval of cheaper rival drug

2019-06-12 09:30:01 | Catalyst CPRX Up 14.1% Since Last Earnings Report: Can It Continue?

2019-06-12 08:47:00 | Catalyst Pharmaceuticals Files Federal Lawsuit Against U.S. Food and Drug Administration

2019-06-04 08:03:00 | Catalyst Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference

2019-05-30 08:03:00 | Catalyst Pharmaceuticals Announces Expansion of Firdapse License to Include Japan

2019-05-28 14:33:05 | Catalyst Pharmaceuticals settles patent dispute with Northwestern University

2019-05-22 15:47:07 | Catalyst Pharma CPRX Rides on Successful Launch of Firdapse

2019-05-22 12:57:50 | Edited Transcript of CPRX earnings conference call or presentation 13-May-19 12:30pm GMT

2019-05-18 07:15:48 | 5 Biotech Stocks to Watch in the Second Half of 2019

2019-05-16 11:00:00 | Are These 2 Beaten-Down Biotech Stocks Worth the Risk?

2019-05-14 14:36:06 | Catalyst CPRX Q1 Loss Narrows, Firdapse Off to a Good Start

2019-05-14 08:44:12 | Implied Volatility Surging for Catalyst Pharmaceuticals CPRX Stock Options

2019-05-13 14:00:00 | Catalyst Pharmaceuticals Posts Strong Q1 Sales for Firdapse

2019-05-13 13:10:00 | Why Catalyst Pharmaceuticals Briefly Spiked Today

2019-05-13 12:23:14 | Catalyst Pharmaceuticals Inc CPRX Q1 2019 Earnings Call Transcript

2019-05-13 07:35:11 | Catalyst Pharmaceutical CPRX Reports Q1 Loss, Tops Revenue Estimates

2019-05-13 06:27:28 | Catalyst: 1Q Earnings Snapshot

2019-05-13 06:03:00 | Catalyst Pharmaceuticals Announces First Quarter 2019 Financial Results and Provides Corporate Update

2019-05-11 08:40:14 | The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

2019-05-10 11:59:37 | Why Catalyst Pharmaceuticals Stock Is Jumping Today

2019-05-10 11:11:50 | Here’s Why Analysts Remain Confident on Catalyst CPRX Stock

2019-05-07 12:08:00 | Why Catalyst Pharmaceuticals Is Getting Crushed Today

2019-05-07 11:13:14 | Biopharma Eyes Worst Day in Years on Rival's FDA Nod

2019-05-07 11:10:26 | Catalyst Pharma Plummets On Competition For Pricey LEMS Drug

2019-05-06 19:23:00 | Catalyst Pharma stock plummets after FDA approves competitor's drug

2019-05-06 08:03:00 | Catalyst Pharmaceuticals to Hold First Quarter Financial Results Conference Call and Webcast on Monday, May 13th, 2019

2019-05-03 09:51:01 | What's in Store for Catalyst Pharma CPRX Q1 Earnings?

2019-04-19 14:00:55 | An Intrinsic Calculation For Catalyst Pharmaceuticals, Inc. NASDAQ:CPRX Suggests It's 32% Undervalued

2019-04-17 09:30:01 | Catalyst CPRX Up 58.1% Since Last Earnings Report: Can It Continue?

2019-04-04 10:24:00 | Why Catalyst Pharmaceuticals, Inc. Soared in March

2019-03-31 09:00:00 | 3 Top Biotech Stocks to Buy Right Now

2019-03-26 14:31:50 | Why Wall Street Is Bullish on Catalyst Pharmaceuticals

2019-03-25 08:09:00 | 2 High-Growth Stocks I'd Buy Right Now

2019-03-19 18:16:19 | Edited Transcript of CPRX earnings conference call or presentation 19-Mar-19 12:30pm GMT

2019-03-19 17:23:00 | Why Catalyst Pharmaceuticals Stock Is Popping Today

2019-03-19 14:26:06 | Catalyst CPRX Reports Wider Q4 Loss, Focuses on Firdapse

2019-03-19 07:40:42 | The Daily Biotech Pulse: FDA Nod For Roche And Amphastar, Milestone Payment Kicks In For Affimed

2019-03-18 16:52:23 | Catalyst: 4Q Earnings Snapshot

2019-03-18 16:20:00 | Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update

2019-03-14 13:34:37 | The Catalyst Pharmaceuticals NASDAQ:CPRX Share Price Has Gained 181%, So Why Not Pay It Some Attention?

2019-03-11 08:03:00 | Catalyst Pharmaceuticals to Hold Fourth Quarter Financial Results and Corporate Update Conference Call and Webcast on Tuesday, March 19th, 2019

2019-02-28 13:44:28 | U.S. Senator Sanders urges FDA to allow older versions of $375,000 drug

2019-02-28 08:03:00 | Catalyst Pharmaceuticals Announces Support of Rare Disease Day 2019

2019-02-26 08:03:00 | Catalyst Pharmaceuticals Announces Publication of Phase 3 Clinical Trial Data for Firdapse® for the Treatment of Lambert-Eaton Myasthenic Syndrome

2019-02-21 14:28:05 | Catalyst Pharmaceuticals defends $375,000 drug price after Bernie Sanders rebuke

2019-02-21 09:00:00 | Catalyst Pharmaceuticals Responds to Letter from Senator Bernie Sanders

2019-02-11 14:58:05 | Catalyst Pharma sees net price of drug, once free, topping $300,000

2019-02-06 14:39:06 | Coral Gables company under fire for drug pricing says patient care is 'top priority'

2019-02-05 08:03:00 | Catalyst Pharmaceuticals to Present at the 21st Annual BIO CEO & Investor Conference

2019-02-04 10:34:04 | U.S. Senator Sanders asks why drug, once free, now costs $375k